Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 4/20 | 0.38 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.32 |
| ▸ | USP2 | O75604 | 1/20 | 0.32 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.32 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24248777 | 0.93 | CYP3A4 (0.36) | CYP3A4TDP1ALDH1A1USP2CYP1A2 | |
| SCHEMBL31262988 | 0.82 | TDP1 (0.35) | CYP3A4TDP1CYP1A2 | |
| SCHEMBL16414303 | 0.81 | BUB1 (0.39) | USP2MEN1KMT2A | |
| SCHEMBL23263140 | 0.74 | POLB (0.34) | ALDH1A1CYP2C9 | |
| SCHEMBL20705097 | 0.74 | BUB1 (0.40) | ALDH1A1USP2 | |
| SCHEMBL22214352 | 0.74 | BUB1 (0.40) | ALDH1A1USP2 | |
| SCHEMBL3656333 | 0.73 | TDP1 (0.44) | CYP3A4TDP1ALDH1A1USP2CYP1A2 | |
| SCHEMBL8852955 | 0.72 | CYP3A4 (0.44) | CYP3A4ALDH1A1USP2CYP1A2CYP2C9 | |
| SCHEMBL20705020 | 0.71 | FFAR3 (0.32) | ALDH1A1MEN1KMT2A | |
| SCHEMBL31267911 | 0.71 | FFAR3 (0.32) | ALDH1A1MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230009712-A1 | METHODS AND COMPOSITIONS FOR MODULATING SPLICING | SKYHAWK THERAPEUTICS, INC. | 2023-01-12 | — | — | US | disclosed |
| US-20220048902-A1 | METHODS AND COMPOSITIONS FOR MODULATING SPLICING | SKYHAWK THERAPEUTICS, INC. | 2022-02-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220048902-A1 | METHODS AND COMPOSITIONS FOR MODULATING SPLICING | RBM17, SF3B1, SF3B5 | CYP3A4 4374/4885TDP1 697/4885ALDH1A1 3964/4885 |
| US-20230009712-A1 | METHODS AND COMPOSITIONS FOR MODULATING SPLICING | RBM17, SF3B1, SF3B5 | CYP3A4 4374/4885TDP1 697/4885ALDH1A1 3964/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.